Strategic plan presented for 2026–2028

OSE has announced its strategic plan for the next three years, which is designed to create multiple near-term catalysts. Importantly, it aims to extract maximum value from its lead proprietary candidates, Tedopi and lusvertikimab. For Tedopi, the registrational Phase III ARTEMIA trial in non-small cell lung cancer remains on track to report a futility analysis in Q326, followed by a full readout in Q128. For lusvertikimab, while OSE was previously planning a Phase IIb trial and precision medicine approach in ulcerative colitis (UC), the company now plans to target less capital-intensive indications, such as speciality/rare diseases; further details will be disclosed in early 2026. Management has also communicated it will seek partnership...